Drug Trial Radar · NCT03054285
Does Short-Term Anti-Seizure Prophylaxis After Traumatic Brain Injury Decrease Seizure Rates?
Last checked: Nov 19, 2026Latest source record: Aug 6, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
2,300
Planned (sponsor's estimate)
Start
Jul 1, 2017
Primary completion
Apr 1, 2020
Study completion Apr 1, 2021
Sponsor
- Lead sponsor
- Loyola UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 15, 2017
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to prospectively assess in randomized fashion whether short term anti-seizure prophylaxis in traumatic brain injured patients decreases the incidence of seizures in the early post-injury period. A secondary objective is to evaluate whether there are differences in mortality, hospital length of stay, functional outcome at hospital discharge, hospital cost, discharge status (home, rehabilitation facility, etc.) for patients who receive and do not receive anti-seizure prophylaxis.
Conditions
- Seizures
- Traumatic Brain Injury
Interventions
LevetiracetamDrug
Participants assigned to the experimental arm will receive a seven day course of levetiracetam for post-traumatic brain injury
Primary outcomes
What the sponsor says the trial is designed to measure.
- Seizures (count of seizures)Time frame: 30 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Loyola University Medical Center
Maywood, Illinois · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.